PATENT CLAIM ANALYSIS

Application Number: 16174089
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "134100"]

Abstract:
Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Claim (Index 6):
The method of  claim 1 , wherein the population of genetically engineered human hematopoietic cells comprises human hematopoietic cells selected from the group consisting of a hematopoietic stem cell, a progenitor cell, a myeloid progenitor cell, a lymphoid progenitor cell, a myeloid cell, a lymphoid cell, and any combination(s) thereof.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.26923
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15655432', '14303331', '15821170', '15934770', '13548148']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7435990108472315
- 35 USC 102 Novelty (BERT): 0.6532389214698664
- Combined Prediction Score: 0.734563001909495
- Mean Citation Score: 435.621612
- Max Citation Score: 693.0727
- Similarity Product: 591.1078451162815

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test